Mirum Pharmaceuticals Inc MIRM

$91.58 -2.41 (-2.56%)

Valuation

Market cap
6,135,855,000
Revenue TTM
$521,310,000
Net income TTM
$-23,360,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-4.48%
Debt to equity
0.00

Trading

Volume
506,400
Avg volume
741,882
Day's range
$91.04 – $94.36
Shares out
65,282,000
Stochastic %K
69%
Beta
0.75
Analysts
Strong Buy
Price target
$151.13

Price

Company profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the Unite...

Show more

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 667 4085
Website
https://www.mirumpharma.com
Address
989 East Hillsdale Boulevard, Suite 300, Foster City, United States

Latest news

Stocktwits

Merlintrader Nov 12, 7:29 PM
New on Merlintrader: the $MIRM stock hub. Mirum's brelovitug met the primary endpoint in the Phase 3 AZURE-4 study in hepatitis delta (Nov 10). Q3 net product sales were 185.7 million dollars, with 500.5 million of cash and investments. Next: VANTAGE PBC topline in Q1 2027. Full $MIRM stock hub: https://www.merlintrader.com/mirum-pharmaceuticals-mirm-stock-hub/ Not investment advice.
0 replies
LongLongStock Nov 12, 10:01 AM 2 replies
TalkMarkets Nov 11, 11:45 PM
#AI Is Coming For #Biopharma - Winners & Losers $MIRM $RVMD $CVS $INCY $LLY https://talkmarkets.com/article/ai-is-coming-for-biopharma-winners-losers
0 replies
dgbio Nov 10, 4:33 PM
$MIRM Fierce's take on brelo: https://www.fiercebiotech.com/biotech/mirum-scores-again-hepatitis-d-phase-3-setting-stage-fda-run
0 replies
LMXPERTEN Nov 10, 1:37 PM
$MIRM listened in to the call! My takeaways. 1. strong confidence in NDA for volixi H1 2027. Would be complete surprise if FDA says no. 2. CFO confirmed strong growth coming years, pos cashflow 2027. HDV numbers in particular but MIRM numbers in general on conservative side. Room for upside!
0 replies
Datum Nov 10, 1:08 PM
$MIRM jeeez i thought we were taking a haircut
0 replies
Rayvio_News_Filter Nov 10, 12:42 PM
$MIRM 🏥 Mirum Pharmaceuticals, Inc. announced that the primary endpoint was met in the Phase 3 AZURE-4 study of brelovitug for chronic hepatitis delta virus, the second of two Phase 3 studies planned for its U.S. registration package. Timely market event
0 replies
LMXPERTEN Nov 10, 12:38 PM
$MIRM AZURE-4 data! Primary endpoint met!
1 replies